Is the Mayne Pharma Group Ltd share price in the buy zone after today’s news?

Unfortunately for its shareholders this morning the Mayne Pharma Group Ltd (ASX: MYX) share price has tumbled lower despite the release of a positive announcement.

In early trade the pharmaceutical company’s shares are down almost 2% to $1.02.

What was the announcement?

This morning Mayne Pharma announced that it had gained approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for doxycycline hyclate immediate release tablets.

As a result the company has immediately commenced a commercial launch to customers in the United States.

Doxycycline hyclate immediate release tablets are generic versions of Acticlate tablets. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.

According to the release, annual sales of the Acticlate in the United States were approximately US$250 million for the twelve months to April 2017.

Should you invest?

Whilst the sales from this drug are unlikely to move the needle significantly in the future, it is just one of a number of drugs that Mayne Pharma has in its pipeline.

Management estimates that it markets more than 50 products and has a growing pipeline of more than 40 products targeting markets with sales of greater than US$7 billion.

Clearly there is significant growth potential from these drugs if things stay the same way. However, with President Trump intent on cutting the price of generic drugs, it is difficult to gauge the impact this will have on its future sales.

Whilst I believe Mayne Pharma is likely to be a great long-term buy and hold investment, I’m not convinced that its share price has found its bottom yet. Especially with short interest continuing to rise.

So for this reason I would suggest investors hold off an investment for the time being and focus on other healthcare shares like CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC).

As well as Ramsay and CSL, these growth shares could also be great buy and hold investments in my opinion.

Each has been growing like wildfire and I expect more of the same in the future.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.